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gressionOsteoarthritis (OA), type 2diabetes, andobesity are commondis-
eases in developed and (increasingly) developing countries. They
share many risk factors including aging, unhealthy dietary patterns,
and physical inactivity, but may also be linked by systemic factors
such as inﬂammation and insulin resistance1. Hyperglycemia often
co-exists with obesity (particularly central obesity), hypertension,
and dyslipidemia (elevated levels of triglycerides and low levels of
high density lipoprotein cholesterol). This mingling of “common
soil” metabolic diseases has been codiﬁed into the concept of the
Metabolic Syndrome, a risk factor for diabetes and cardiovascular
diseases (CVD). Although there are several slightly different deﬁni-
tions of Metabolic Syndrome, all constructs consider the syndrome
present if three or more of ﬁve risk factors are present2. Whether
collapsing multiple continuous variables into a single dichotomous
variable adds clinical or predictive value is a matter of debate in the
diabetes and cardiovascular world3, and the syndrome excludes
other strong risk factors such as age, family history, and smoking.
Nevertheless, some argue that the Metabolic Syndrome concept
highlights the need to screen people with one metabolic disease
for others, and to simultaneously address multiple risk factors2.
In this issue of Osteoarthritis and Cartilage, Eymard and col-
leagues describe how they leveraged data from the placebo arm
of the SEKOIA clinical trial to evaluate the associations between
various metabolic diseases and baseline knee OA symptoms and
progression of knee OA4. Obesity was highly signiﬁcantly associated
with worse WOMAC subscores at baseline, whereas there were no
signiﬁcant associations with patient-reported diabetes, hyperten-
sion, dyslipidemia, or cardiac disease. When obesity, diabetes, hy-
pertension, and dyslipidemia were combined into a (non-
standard) Metabolic Syndrome measure, there was no association
with baseline WOMAC scores. The situation was different for pro-
gression of knee OA during the trial: only diabetes was associated
with greater annualized rates of joint space narrowing, and in sub-
group analyses the link between diabetes and OA progression was
seen only in men.
What are we to make of these ﬁndings? The strengths of the
study include well-validated measures of symptoms and physicala.2015.01.013.
ternational. Published by Elsevier Lat baseline and use of an objective blindedmeasure of pro-
of joint space narrowing in the knee. Potential weaknesses
include the population being Caucasian (a population at somewhat
lower risk of diabetes), use of self-report to determine disease sta-
tus (in the U.S., more than one-quarter of thosewith type 2 diabetes
are undiagnosed5 and it is likely that many people are unaware of
their lipid status), and use of an atypical deﬁnition of Metabolic
Syndrome (although use of a standard deﬁnition likely would not
have changed the ﬁndings).
The signiﬁcant association of obesity with baseline symptoms
and physical functioning, although not a new ﬁnding, warrants
emphasis. It is likely that the prevention of obesity would signiﬁ-
cantly reduce incidence of symptomatic knee OA, but there is
hope even for the millions of people today with both obesity and
knee OA. The large NIH-funded Look AHEAD trial examined the ef-
fects of weight loss on cardiovascular outcomes in obese patients
with type 2 diabetes. Even though the primary CVD outcome was
negative6, the study documented multiple other beneﬁts of weight
loss (improved glycemic control, reductions in polypharmacy, im-
provements in functional status, reduction in urinary incontinence,
improved depression scores, and others7). Pertinent to this discus-
sion is the ﬁnding that for Look AHEAD participants with knee OA,
weight loss through an intensive lifestyle intervention led to signif-
icant improvements in WOMAC scores8.
The association of diabetes with OA progression (but not with
baseline WOMAC scores) in the analysis by Eymard and colleagues
is a bit harder to translate into clinical action. There are clearly links
between hyperglycemia and adverse effects on cartilage, perhaps
mediated by glycation and inﬂammation, as described in the paper.
Long-standing type 1 diabetes (arguably amore “pure”model of hy-
perglycemia without other metabolic diseases) is associated with
cheiroarthopathy, function-impairing stiffness of connective tissue
in the hands, feet, shoulders, and other areas9. That diabetes was
linked to OA progression in the SEKOIA trial ﬁts this mechanistic
framework, yet it is hard to explain the lack of association of dia-
beteswith any baselinemeasures of patient-reported OA symptoms
or physical function. The gender discrepancy is also a bit of a puzzle.
As the authors note,men aremore likely to develop diabetic periph-
eral neuropathy (so are taller people), and neuropathy might alter
joint mechanics and contribute to more rapid progression of OA.
Eymard et al. conclude their discussion with the proposal that
tight glycemic control in those with diabetes might reduce rates
of knee OA progression, and suggest longitudinal trials of the hy-
pothesis. The diabetes community has been roiled by the pitfalls
of noting associations of diabetes (or glycemic control in those
with diabetes) to adverse outcomes and then assuming that more
stringent interventions on hyperglycemia would reduce the associ-
ated adverse outcomes.We have known for decades that the extenttd. All rights reserved.
Editorial / Osteoarthritis and Cartilage 23 (2015) 839e840840and duration of hyperglycemia (measured, for example, by hemo-
globin A1c levels) in those with diabetes is strongly linked to risk
of the microvascular complications of diabetes (retinopathy, neu-
ropathy, nephropathy) and to risk of CVD events and premature
mortality. Large clinical trials of intensive vs standard glycemic con-
trol in patients with type 1 and type 2 diabetes have repeatedly
shown that microvascular complication risk is lowered with inten-
sive glycemic control10.
For cardiovascular disease (the largest killer of people with dia-
betes), however, outcomes of randomized trials of intensive glyce-
mic control have been more sobering. Post-trial follow-up of
cohorts from the original microvascular outcome trials (done in
fairly healthy, recently diagnosed patients with type 1 or type 2 dia-
betes) have found lower rates of major CVD outcomes in those ran-
domized to the intensive arm of the earlier trials. However, more
recent large trials enrolling patients with type 2 diabetes at high
primary or secondary CVD risk, and powered on cardiovascular out-
comes, showed no signiﬁcant reduction in major CVD outcomes
with intensive glycemic control, and one showed an increase in
mortality with intensive glycemic control11.
In similar fashion, the association of diabeteswith progression of
knee OA may not translate into a beneﬁt of intensive glycemic con-
trol on OA. One hint of this possibility comes from long-term follow-
up of the cohort of patients with type 1 diabetes originally enrolled
in the landmark Diabetes Control and Complications trial, which
provided some of the ﬁrst and strongest evidence that intensive gly-
cemic control reduced onset and progression of microvascular com-
plications. These patients were healthy and had relatively short
duration of diabetes at enrollment into the trial. After the random-
ized trial ended in 1993, the majority of study participants have
continued to be followed annually. Although the average hemoglo-
bin A1Cs of the intensive and standard glycemic control arms have
been similar since the intervention trial ended, rates of many
adverse outcomes (including CVD events and mortality) have
consistently been lower in the group originally randomized to
intensive glycemic control. The single exception to this ﬁnding
seems to be cheiroarthropathy. Rates of connective tissue complica-
tions such as adhesive capsulitis of the shoulder have been high in
this population that now has had type 1 diabetes for at least 25
years, and are no different between the two original study arms9.
It remains unclear whether diabetes is a culprit in the progres-
sion or development of OA or whether it is merely an innocent (of
this crime, at least) bystander arising from an environment that can
lead to any number of bad outcomes. Adding OA measures to
ongoing or future diabetes treatment trials may help answer these
questions.
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